Neurofilaments represent a possible valid biomarker, and osteopontin, CHI3L, and CXCL13 are still exploratory biomarkers that seem to be promising candidates for monitoring therapeutic response in MS, but clinical validation is still required (Table 2). The gene discussed is SPP1; the disease is myeloid sarcoma.